KMT2A and acute myeloid leukemia: In the future, targeting HOX expression through Menin-MLL inhibition could thus potentially add to other non-chemotherapic agents, such as dactinomycin or venetoclax, which have recently shown promising anti-leukemic activity in distinct subgroups of NPM1-mutated AML patients [125,126,127].